Company Valuation: North China Pharmaceutical Company.Ltd

Data adjusted to current consolidation scope
Fiscal Period: December 2020 2021 2022 2023 2024 2025
Market Cap 1 16,781 20,452 10,981 9,780 8,870 9,488
Change - 21.87% -46.31% -10.94% -9.3% 6.96%
Enterprise Value (EV) 1 25,126 28,923 20,346 19,939 18,660 19,162
Change - 15.11% -29.65% -2% -6.41% 2.69%
P/E 172x 1,084x -15.9x 1,900x 69.9x 51.7x
PBR 2.74x 3.36x 2.07x 1.84x 1.65x 1.72x
PEG - -13.3x 0x -19x 0x 1.2x
Capitalization / Revenue 1.46x 1.97x 1.05x 0.97x 0.9x 1.03x
EV / Revenue 2.19x 2.79x 1.94x 1.97x 1.89x 2.07x
EV / EBITDA 20.8x 23.7x 15.2x 15.7x 12.9x 12.6x
EV / EBIT 42x 48.2x 32.1x 37.2x 28.3x 30.6x
EV / FCF -30.9x -32x 112x 128x 49.1x 35.2x
FCF Yield -3.24% -3.12% 0.89% 0.78% 2.03% 2.84%
Dividend per Share 2 0.03 0.06 - 0.01 0.03 0.035
Rate of return 0.29% 0.5% - 0.18% 0.58% 0.63%
EPS 2 0.06 0.011 -0.402 0.003 0.074 0.107
Distribution rate 50% 545% - 333% 40.5% 32.7%
Net sales 1 11,493 10,385 10,500 10,120 9,870 9,242
EBITDA 1 1,209 1,221 1,343 1,272 1,447 1,517
EBIT 1 597.9 600.1 634.8 536.4 658.9 627.2
Net income 1 97.32 18.73 -689.2 4.89 127 183.1
Net Debt 1 8,345 8,472 9,366 10,159 9,790 9,674
Reference price 2 10.290 11.920 6.400 5.700 5.170 5.530
Nbr of stocks (in thousands) 16,30,805 17,15,730 17,15,730 17,15,730 17,15,730 17,15,730
Announcement Date 28/04/21 27/04/22 21/04/23 29/03/24 27/03/25 17/04/26
1CNY in Million2CNY
Estimates


P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
- - - - 117.29Cr
41.42x14.01x31.06x0.48% 1,26300Cr
39.99x6.71x18.89x1.95% 66TCr
36.71x8.6x17.71x2.35% 52TCr
21.74x5.27x13.12x2.48% 39TCr
97.38x6.07x25.8x2.28% 37TCr
23.19x5.95x14.36x2.69% 31TCr
24.47x4.89x13.87x1.77% 29TCr
29.55x7.53x13.48x2.16% 25TCr
-40.86x7.45x46.76x1.94% 21TCr
Average 30.40x 7.39x 21.67x 2.01% 42.63TCr
Weighted average by Cap. 36.41x 8.82x 22.82x 1.69%

Y-o-Y evolution of P/E

Valuation ratios - P/E - North China Pharmaceutical Company.Ltd

Historical PBR trend

Valuation ratios - PBR - North China Pharmaceutical Company.Ltd

Evolution Enterprise Value / Sales

Valuation ratios - VE_REV - North China Pharmaceutical Company.Ltd

Change in Enterprise Value/EBITDA

Valuation ratios - VE_EBITDA - North China Pharmaceutical Company.Ltd

  1. Stock Market
  2. Stocks
  3. 600812 Stock
  4. Valuation North China Pharmaceutical Company.Ltd